HRK
(Harakiri, BCL2 Interacting Protein (Contains Only BH3 Domain) (HRK))
Protein Region
N-Term
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
Attributs du produit
This is a synthetic peptide designed for use in combination with anti-HRK antibody (Catalog #: ARP46364_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Concentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Conseil sur la manipulation
Avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Antigène
HRK
(Harakiri, BCL2 Interacting Protein (Contains Only BH3 Domain) (HRK))
Synonymes
DP5 Peptide, HARAKIRI Peptide, AI838259 Peptide, Bid3 Peptide, harakiri Peptide, Dp5 Peptide, harakiri, BCL2 interacting protein Peptide, harakiri, BCL2 interacting protein (contains only BH3 domain) Peptide, HRK Peptide, Hrk Peptide
Sujet
Activator of apoptosis Hrk regulates apoptosis through interaction with death-repressor proteins Bcl-2 and Bcl-X(L). The HRK protein lacks significant homology to other BCL2 family members except for an 8-amino acid region that was similar to the BCL2 hom
Alias Symbols: DP5, HARAKIRI
Protein Interaction Partner: BCL2,BCL2,BCL2A1,BCL2L1,BCL2L1,BCL2L1,BCL2L2,BNC1,BAD,BCL2,BCL2A1,BCL2L1,BCL2L2,C1QBP,BCL2,BCL2A1,BCL2L1,BCL2L2,MCL1